Corporate governance


The following information is disclosed in accordance with AIM Rule 26


Business description Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile.
Country of incorporation and main country of operation Country of incorporation: England and Wales

Company registration number: 09818395

Main country of operation: UK

Current constitutional documents Oncimmune’s current constitutional documents are available on the Company documents page
Details of other exchanges or trading platforms Other than AIM, the Company’s shares are not admitted to or traded on any other exchanges or trading platforms.
Significant Shareholders and Shares in Issue Please see our Shareholder analysis page for details
Restrictions on transfers of securities There are no current restrictions on the transfer of Oncimmune’s AIM securities.
Annual Accounts Oncimmune’s annual reports for the last three years are available on the Reports page
Regulatory news Regulatory news announcements can be found on Oncimmune’s RNS news page
AIM admission document Oncimmune’s most recent admission document is available on the Company documents page
Corporate governance The Board has adopted the 2018 Quoted Companies Alliance Corporate Governance Code (the “QCA Code”) as the basis of the Group’s governance framework. More information about how we apply the QCA code is available on the Governance page
Directors’ names and biographies The names, responsibilities and a brief biography of each member of the Board of Directors, including committee membership, is available on the Board page
Board of Directors Committees Details of the Committees of Oncimmune’s Board of Directors and their responsibilities are described on the Governance page
UK City Code on Takeovers and Mergers Oncimmune Holdings Plc is subject to the UK City Code on Takeovers and Mergers.
Company advisers Details of Oncimmune’s Nominated Advisor and other key key advisors are available on Advisors page

Last reviewed: 24th April 2024